Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars - Full Text View

Sponsored by:	Renovo
Information provided by:	Renovo
ClinicalTrials.gov Identifier:	NCT00469235

Purpose

This trial will assess the safety and efficacy of 50 and 200ng Juvista per linear cm of wound margin administered by intradermal injection following the excision of keloid scars on the ear lobe. Ear lobe keloids commonly occur after ear piercing and can be particularly distressing for patients as they are very difficult to conceal and are usually bilateral. As the recurrence rate and growth rate of keloids can vary significantly between individuals, trial subjects will have bilateral ear lobe keloids and will act as their own control. One ear lobe will be treated with Juvista following keloid excision and one with placebo.

Condition	Intervention	Phase
Keloid	Drug: Avotermin	Phase I Phase II

MedlinePlus related topics: Scars

Drug Information available for: Avotermin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety Study
Official Title:	A Single-Centre, Double Blind, Randomised, Rising Dose Tolerance Study to Investigate the Safety of Juvista When Administered Following Excision of Ear Lobe Keloids.

Further study details as provided by Renovo:

Primary Outcome Measures:

Frequency of adverse events [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Keloid reoccurrence [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	20
Study Start Date:	June 2007
Estimated Study Completion Date:	March 2009
Estimated Primary Completion Date:	June 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Placebo Comparator 50ng dose group	Drug: Avotermin 10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure. 10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.
2: Placebo Comparator 200ng dose group	Drug: Avotermin 10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure. 10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.

Arms

Assigned Interventions

1: Placebo Comparator

50ng dose group

Drug: Avotermin

10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.

10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.

2: Placebo Comparator

200ng dose group

Drug: Avotermin

10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.

10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.

Eligibility

Ages Eligible for Study:	18 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients aged 18-85 years who have given written informed consent.
Patients with bilateral ear lobe keloid scars suitable for surgical excision which will result in a single wound on each ear lobe no greater than 2cm long and restricted to the skin, fat and fibrous tissue of the ear lobe.
Patients with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol.
Female patients of child bearing potential who are using a highly effective method(s) of contraception and agree to do so from at least the screening visit until one month after administration of the final study dose.

Exclusion Criteria:

Patients who have had ear lobe keloids treated with irradiation, cryosurgery, corticosteroids, or other pharmacological agents in the three months prior to the first trial dose administration.
Patients with a history of a bleeding disorder.
Patients who on direct questioning and/or physical examination have past or present evidence of eczema or psoriasis local to the site of administration, uncontrolled diabetes (fasting plasma glucose concentration consistently at or above 7.0mmol 1-1 (126 mg dl-1), severely immunocompromised patients and/or malignant skin tumours e.g. melanomas, squamous or basal cell carcinomas.
Patients with a skin disorder, not related to the keloid disease, that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial
Patients with a history of malignancy in the last 5 years.
Patients with a history of hypersensitivity to any of the drugs or dressings used in this trial.
Patients who are taking, or have taken any investigational product or participated in a clinical trial in the three months prior to first trial dose administration.
Patients undergoing investigations or changes in management for an existing medical condition.
Patients who, in the opinion of the Investigator, are unlikely to complete the trial for whatever reason.
Female patients who are pregnant or lactating.
Patients with a creatinine clearance (CLcr) of 80ml/min or less.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00469235

Locations

United States, Missouri
Body Aesthetic Plastic Surgery and Skincare Center
St Louis, Missouri, United States, 63141

Sponsors and Collaborators

Renovo

Investigators

Principal Investigator:

Leroy Young, MD

Body Aesthetic Plastic Surgery and Skincare Centre

More Information

No publications provided

Responsible Party:	Renovo Ltd ( Renovo Ltd )
Study ID Numbers:	RN1001-0064
Study First Received:	May 3, 2007
Last Updated:	October 22, 2008
ClinicalTrials.gov Identifier:	NCT00469235 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Skin Diseases
Collagen Diseases
Keloid
Connective Tissue Diseases
Cicatrix

Additional relevant MeSH terms:

Skin Diseases
Collagen Diseases
Keloid
Connective Tissue Diseases
Cicatrix

ClinicalTrials.gov processed this record on May 06, 2009